PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2858160-2	1985	The recent description of the drug proglumide as a specific, competitive cholecystokinin (CCK)/gastrin receptor antagonist has permitted reevaluation of the role of CCK in this process.	Proglumide	35-45	cholecystokinin	Canis lupus familiaris	73-88	
2858160-2	1985	The recent description of the drug proglumide as a specific, competitive cholecystokinin (CCK)/gastrin receptor antagonist has permitted reevaluation of the role of CCK in this process.	Proglumide	35-45	cholecystokinin	Canis lupus familiaris	90-93	
2858160-2	1985	The recent description of the drug proglumide as a specific, competitive cholecystokinin (CCK)/gastrin receptor antagonist has permitted reevaluation of the role of CCK in this process.	Proglumide	35-45	cholecystokinin	Canis lupus familiaris	165-168	
2858160-3	1985	In chronic pancreatic fistula dogs, dose-response studies were performed to determine the effect of proglumide on the pancreatic responses to octapeptide of CCK (CCK-OP), intravenous bethanechol, intraduodenal amino acids, and intraduodenal fat.	Proglumide	100-110	cholecystokinin	Canis lupus familiaris	157-160	
2858160-4	1985	Pancreatic volume, protein, and bicarbonate outputs to all doses of CCK-OP were inhibited significantly (P less than 0.05) in a competitive manner, consistent with the proposed mode of action of proglumide.	Proglumide	195-205	cholecystokinin	Canis lupus familiaris	68-74	
2858160-7	1985	If indeed proglumide is a specific CCK receptor antagonist, these results support the hypothesis that CCK is the major mediator of the intestinal phase of exocrine pancreatic secretion.	Proglumide	10-20	cholecystokinin	Canis lupus familiaris	35-38	
2858160-7	1985	If indeed proglumide is a specific CCK receptor antagonist, these results support the hypothesis that CCK is the major mediator of the intestinal phase of exocrine pancreatic secretion.	Proglumide	10-20	cholecystokinin	Canis lupus familiaris	102-105